{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:54Z","timestamp":1789122774400,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We compared the presence of additional chromosomal abnormalities (ACAs,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009345) with a referent group with no ACAs (\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009169) (noACAs) in patients with Ph+ ALL receiving TKI before transplantation. The groups did not differ significantly in age, gender, or interval from diagnosis to transplantation. More patients with ACAs received PB grafts (86.4% vs. 78.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03), while more patients in the noACAs group received myeloablative conditioning (87% vs. 75.9%,\n                    <jats:italic>p\u2009<\/jats:italic>\n                    =\u20090.003). Day 30 ANC (\u226510\n                    <jats:sup>9<\/jats:sup>\n                    \/L) was 97.9% vs. 98.2%, and day 60 platelet count (\u226520\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L) was 93.9% vs. 95.5%. Day 100 acute GVHD grades II-IV was 26.4% vs. 31%, and of grades III-IV was 8.6% vs. 9.7%. 4-year chronic GVHD was 40.5% vs. 39.9%, and the proportion of extensive chronic GVHD was 19.3% vs. 20.1%. 4-year NRM was 13.1% vs. 13.5%, and 4-year RI was 19.2% vs. 21.1%; 4-year LFS and OS were 67.7% vs. 65.4% and 76.3% vs. 78.5%. 4-year GRFS was 48.5% vs. 45%, respectively. In multivariable analysis, having ACAs and the number of ACAs did not significantly affect transplant outcomes. Administration of a TKI upfront, followed by transplantation, may overcome the poor prognostic influence of ACAs in Ph+ ALL.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-02970-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:22:26Z","timestamp":1783966946000},"page":"1246-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-6063","authenticated-orcid":false,"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3085-6539","authenticated-orcid":false,"given":"Nathalie","family":"Dhedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lioure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-5804","authenticated-orcid":false,"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-4042","authenticated-orcid":false,"given":"Rodrigo","family":"Martino Bufarull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Ben Abdeljelil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2970_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-3-031-84988-6_8","volume":"1475","author":"R Swoboda","year":"2025","unstructured":"Swoboda R, Nagler A. Acute Lymphoid Leukemia: Is Transplant Indicated for Philadelphia Chromosome Positive ALL? Adv Exp Med Biol. 2025;1475:149\u201366.","journal-title":"Adv Exp Med Biol"},{"key":"2970_CR2","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms the superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood. 2009;113:4489\u201396.","journal-title":"Blood"},{"key":"2970_CR3","first-page":"14.e1","volume":"31","author":"S Giebel","year":"2025","unstructured":"Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U, et al. Impact of the type of tyrosine kinase inhibitor (imatinib or dasatinib) used before allo-HCT on outcome of patients with Philadelphia-positive acute lymphoblastic leukemia. A study on behalf of the Acute Leukemia Working Party of the EBMT. Transpl Cell Ther. 2025;31:14.e1\u201314.e10.","journal-title":"Transpl Cell Ther"},{"key":"2970_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Xuang X, Haddad FG, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98:493\u2013501.","journal-title":"Am J Hematol"},{"key":"2970_CR5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024;331:1814\u201323.","journal-title":"JAMA"},{"key":"2970_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2970_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the Dasatinib-Blinatumomab Protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"2970_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, DeAngelo DJ, G\u00f6kbuget N, Advani AS, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2021;127:905\u201313.","journal-title":"Cancer"},{"key":"2970_CR9","first-page":"17","volume":"68","author":"I Danylesko","year":"2020","unstructured":"Danylesko I, Chowers G, Shouval R, Besser MJ, Jacoby E, Shimoni A, et al. Treatment with anti-CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med. 2020;68:17\u201322.","journal-title":"Curr Res Transl Med"},{"key":"2970_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"2970_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","volume":"36","author":"Y Sasaki","year":"2022","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36:1253\u201360.","journal-title":"Leukemia"},{"key":"2970_CR12","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2017-07-796862","volume":"131","author":"H Pfeifer","year":"2018","unstructured":"Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obl\u00e4nder J, et al. Genomic CDKN2A\/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018;131:1464\u201375.","journal-title":"Blood"},{"key":"2970_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3324\/haematol.2018.196055","volume":"104","author":"AL Fedullo","year":"2019","unstructured":"Fedullo AL, Messina M, Elia L, Piciocchi A, Gianfelici V, Lauretti A, et al. Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2019;104:312\u20138.","journal-title":"Haematologica"},{"key":"2970_CR14","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41375-024-02319-2","volume":"38","author":"I Abou Dalle","year":"2024","unstructured":"Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia. 2024;38:1876\u201384.","journal-title":"Leukemia"},{"key":"2970_CR15","first-page":"2309","volume":"10","author":"T Shi","year":"2020","unstructured":"Shi T, Huang X, Zhu L, Li X, Li L, Ye X. Adult Ph-positive acute lymphoblastic leukemia: current concepts in cytogenetic abnormalities and outcomes. Am J Cancer Res. 2020;10:2309\u201318.","journal-title":"Am J Cancer Res"},{"key":"2970_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04736.x","volume":"124","author":"M Wetzler","year":"2004","unstructured":"Wetzler M, Dodge RK, Mr\u00f3zek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004;124:275\u201388.","journal-title":"Br J Haematol"},{"key":"2970_CR17","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.1097\/HS9.0000000000000899","volume":"7","author":"S Nishiwaki","year":"2023","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. Hemasphere. 2023;7:e899.","journal-title":"Hemasphere"},{"key":"2970_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24625","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, et al. Poor outcomes associated with +der (22)t(9;22) and -9\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92:238\u201343.","journal-title":"Am J Hematol"},{"key":"2970_CR19","doi-asserted-by":"publisher","first-page":"106176","DOI":"10.1016\/j.leukres.2019.106176","volume":"84","author":"P Jain","year":"2019","unstructured":"Jain P, Gu J, Kanagal-Shamanna R, Tang Z, Patel KP, Yao H, et al. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res. 2019;84:106176.","journal-title":"Leuk Res"},{"key":"2970_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.bbmt.2015.03.021","volume":"21","author":"I Aldoss","year":"2015","unstructured":"Aldoss I, Stiller T, Cao TM, Palmer JM, Thomas SH, Forman SJ, et al. Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1326\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2970_CR21","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/j.bbmt.2018.06.006","volume":"24","author":"Y Akahoshi","year":"2018","unstructured":"Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, et al. Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era. Biol Blood Marrow Transpl. 2018;24:2009\u201316.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2970_CR22","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00277-024-05871-0","volume":"103","author":"J Zheng","year":"2024","unstructured":"Zheng J, Zhao Y, Luo Y, Yu J, Lai X, Wang J, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of adults patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis. Ann Hematol. 2024;103:2983\u201391.","journal-title":"Ann Hematol"},{"key":"2970_CR23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u20133320.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2970_CR24","first-page":"825","volume":"15","author":"D Predivorce","year":"1995","unstructured":"Predivorce D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2970_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"2970_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2970_CR27","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/."},{"key":"2970_CR28","unstructured":"A language and environment for statistical computing. Vienna, Austria: R Core Team: R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/."},{"key":"2970_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5:1102\u20139.","journal-title":"Blood Adv"},{"key":"2970_CR30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3324\/haematol.2021.278304","volume":"107","author":"A Visentin","year":"2021","unstructured":"Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, et al. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica. 2021;107:868\u201376.","journal-title":"Haematologica"},{"key":"2970_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00277-009-0720-z","volume":"88","author":"Y Li","year":"2009","unstructured":"Li Y, Qiu L, Zou D, Zhao Y, Mi Y, Wang J. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Ann Hematol. 2009;88:1069\u201377.","journal-title":"Ann Hematol"},{"key":"2970_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3324\/haematol.11891","volume":"93","author":"M Yanada","year":"2008","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica. 2008;93:287\u201390.","journal-title":"Haematologica"},{"key":"2970_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1046\/j.1365-2141.1996.d01-1968.x","volume":"95","author":"H Rieder","year":"1996","unstructured":"Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, G\u00f6kbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 1996;95:678\u201391.","journal-title":"Br J Haematol"},{"key":"2970_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/10428194.2017.1326596","volume":"59","author":"C Motll\u00f3","year":"2018","unstructured":"Motll\u00f3 C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59:146\u201354.","journal-title":"Leuk Lymphoma"},{"key":"2970_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70117","volume":"9","author":"A Bazarbachi","year":"2025","unstructured":"Bazarbachi A, Labopin M, Dalle IA, Yakoub-Agha I, Soci\u00e9 G, Schroeder T, et al. Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party. Hemasphere. 2025;9:e70117.","journal-title":"Hemasphere"},{"key":"2970_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ajh.25338","volume":"94","author":"NJ Short","year":"2019","unstructured":"Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019;94:257\u201365.","journal-title":"Am J Hematol"},{"key":"2970_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"2970_CR38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41409-025-02667-2","volume":"60","author":"S Giebel","year":"2025","unstructured":"Giebel S, Labopin M, Swoboda R, Blaise D, Yakoub-Agha I, Nguyen S, et al. Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2025;60:1325\u201332.","journal-title":"Bone Marrow Transpl"},{"key":"2970_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02983538","volume":"79","author":"H Iida","year":"2004","unstructured":"Iida H, Sao H, Kitaori K, Gotoh S, Yazaki M, Kojima S, et al. Twenty Years\u2019 Experience in Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome\u2014Positive Acute Lymphoblastic Leukemia in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol. 2004;79:79\u201384.","journal-title":"Int J Hematol"},{"key":"2970_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, et al. Outcome of haploidentical versus matched sibling donors in hematopieticstem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation. J Hematol Oncol. 2021;14:53.","journal-title":"J Hematol Oncol"}],"updated-by":[{"DOI":"10.1038\/s41409-026-03022-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02970-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02970-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02970-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:32Z","timestamp":1789119452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02970-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2970"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02970-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the article title has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-026-03022-9","URL":"https:\/\/doi.org\/10.1038\/s41409-026-03022-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The scientific boards of the Acute Leukemia Working Party of the EBMT approved this study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}